CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 43 enrolled
Drug / intervention
BIA 2-093 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02284854
NCT02284854Phase 1Completed
CompareCT.gov

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine in Healthy Subject

Bial - Portela C S.A.·interventional·Posted Nov 6, 2014·Updated Jan 8, 2015

In Brief

A Phase 1 clinical trial evaluating BIA 2-093 and Carbamazepine for Epilepsy. Completed, enrolled 43 participants.

Detailed Summary

Open-label study in two parallel groups of 20 healthy subjects each. Group A assessed the effect of CBZ on ESL pharmacokinetics, and Group B assessed the effect of ESL on CBZ pharmacokinetics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 6, 2014
Enrollment StartJul 1, 2009
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.7 years ago

Interventions

BIA 2-093drug

Carbamazepinedrug